An open-label, prospective study to evaluate social function and overall improvement of extended-release paliperidone treatment in Thai schizophrenia patients

QR Code

An open-label, prospective study to evaluate social function and overall improvement of extended-release paliperidone treatment in Thai schizophrenia patients

Chawanun Charnsil,1 Salinee Vongpanich21Department of Psychiatry, Chiang Mai University, Chiang Mai, Thailand; 2Medical Affairs Department, Janssen-Cilag, Bangkok, ThailandBackground: Previous studies with extended-release (ER) paliperidone have reported an effective outcome in terms of personal and...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Charnsil C, Vongpanich S
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2013
Sujets:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Accès en ligne:	https://doaj.org/article/7b276e8a2e404f87b4eff4ad30b12e26
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Effects of paliperidone extended release on hostility among Thai patients with schizophrenia
par: Jariyavilas A, et autres
Publié: (2017)

An open-label, flexible-dose study of paliperidone extended-release in Chinese patients with first-onset psychosis
par: Si TM, et autres
Publié: (2015)

Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia
par: Ibrahim Turkoz, et autres
Publié: (2008)

Treatment satisfaction with paliperidone extended-release tablets: open-label study in schizophrenia patients dissatisfied with previous antipsychotic medication
par: Yang FD, et autres
Publié: (2017)

The social functional outcome of being naturalistically treated with paliperidone extended-release in patients with schizophrenia
par: Nakagawa R, et autres
Publié: (2015)

Improvement in social and cognitive functioning associated with paliperidone extended-release treatment in patients with schizophrenia: a 24-week, single arm, open-label study
par: Shi C, et autres
Publié: (2016)

Paliperidone extended-release tablets in Chinese patients with schizophrenia: meta-analysis of randomized controlled trials
par: Cai SL, et autres
Publié: (2015)

Efficacy, tolerability, and safety of oral paliperidone extended release in the treatment of schizophrenia: a 24-week, open-label, prospective switch study in different settings in Taiwan
par: Chen CY, et autres
Publié: (2018)

Role of paliperidone extended-release in treatment of schizoaffective disorder
par: Carla M Canuso, et autres
Publié: (2010)

The role of paliperidone extended release for the treatment of bipolar disorder
par: Marino J, et autres
Publié: (2012)

Efficacy and safety of flexibly dosed paliperidone palmitate in Chinese patients with acute schizophrenia: an open-label, single-arm, prospective, interventional study
par: Si TM, et autres
Publié: (2015)

Reliability and validity of the Thai version of the Calgary Depression Scale for Schizophrenia
par: Suttajit S, et autres
Publié: (2013)

Safety and efficacy of paliperidone extended-release in Chinese patients with schizophrenia: a 24-week, open-label extension of a randomized, double-blind, placebo-controlled study
par: Zhang H, et autres
Publié: (2016)

Efficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an open-label, prospective, noncomparative study
par: Li HF, et autres
Publié: (2015)

Twelve-month, prospective, open-label study of repetitive transcranial magnetic stimulation for major depressive disorder in partial remission
par: Charnsil C, et autres
Publié: (2012)

Once-monthly paliperidone injection for the treatment of schizophrenia
par: Delia Bishara
Publié: (2010)

The management of schizophrenia: focus on extended-release quetiapine fumarate
par: Peuskens J
Publié: (2011)

Update on extended release quetiapine fumarate in schizophrenia and bipolar disorders
par: El-Khalili N
Publié: (2012)

Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia
par: Zhang F, et autres
Publié: (2015)

The safety and effectiveness of open-label extended-release carbamazepine in the treatment of children and adolescents with bipolar I disorder suffering from a manic or mixed episode
par: Findling RL, et autres
Publié: (2014)

Interaction between paliperidone extended release and TS-1&reg;, an oral anticancer drug containing a 5-fluorouracil derivative, in a schizophrenic patient
par: Yasui-Furukori N, et autres
Publié: (2013)

Gabapentin adjunctive to risperidone or olanzapine in partially responsive schizophrenia: an open-label pilot study
par: Adel Gabriel
Publié: (2010)

An open-label study of algorithm-based treatment versus treatment-as-usual for patients with schizophrenia
par: Hirano J, et autres
Publié: (2013)

Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia
par: Sliwa JK, et autres
Publié: (2012)

Randomized, placebo-controlled, double-blind study assessing the efficacy and safety of paliperidone palmitate in Asian patients with schizophrenia
par: Takahashi N, et autres
Publié: (2013)

Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study
par: Zhao JP, et autres
Publié: (2017)

Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics
par: Alphs L, et autres
Publié: (2013)

Critical evaluation of paliperidone in the treatment of schizophrenia in Chinese patients: a systematic literature review
par: Zhang LL, et autres
Publié: (2016)

A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation
par: An, et autres
Publié: (2015)

Role of extended release quetiapine in the management of bipolar disorders
par: Rayan K Al Jurdi, et autres
Publié: (2010)

Management of obsessive-compulsive disorder with fluvoxamine extended release
par: L&iacute;dia Ordacgi, et autres
Publié: (2009)

Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia
par: Srihari Gopal, et autres
Publié: (2011)

Efficacy of quetiapine in patients with bipolar I and II depression: a multicenter, prospective, open-label, observational study
par: Jeong JH, et autres
Publié: (2013)

Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study
par: Wani RA, et autres
Publié: (2015)

Long-lasting extrapyramidal symptoms after multiple injections of paliperidone palmitate to treat schizophrenia
par: Takada R, et autres
Publié: (2018)

Role of paliperidone palmitate 3-monthly in the management of schizophrenia: insights from clinical practice
par: Lopez A, et autres
Publié: (2019)

Paliperidone ER: a review of the clinical trial data
par: Philip G Janicak, et autres
Publié: (2007)

Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study [Corrigendum]
par: Wani RA, et autres
Publié: (2015)

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
par: Mathews M, et autres
Publié: (2019)

Efficacy, safety, and potential of extended-release lamotrigine in the treatment of epileptic patients
par: Barbara Błaszczyk, et autres
Publié: (2010)